Celularity Statistics
Share Statistics
Celularity has 22.48M shares outstanding. The number of shares has increased by -88.49% in one year.
Shares Outstanding | 22.48M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.93% |
Owned by Institutions (%) | n/a |
Shares Floating | 10.99M |
Failed to Deliver (FTD) Shares | 119.00K |
FTD / Avg. Volume | 10.94% |
Short Selling Information
The latest short interest is 743.72K, so 3.38% of the outstanding shares have been sold short.
Short Interest | 743.72K |
Short % of Shares Out | 3.38% |
Short % of Float | 6.92% |
Short Ratio (days to cover) | 18.95 |
Valuation Ratios
The PE ratio is -0.22 and the forward PE ratio is -6.72.
PE Ratio | -0.22 |
Forward PE | -6.72 |
PS Ratio | 1.93 |
Forward PS | 0.8 |
PB Ratio | 1.07 |
P/FCF Ratio | -1.03 |
PEG Ratio | n/a |
Enterprise Valuation
Celularity Inc. has an Enterprise Value (EV) of 232.10M.
EV / Earnings | -1.18 |
EV / Sales | 10.19 |
EV / EBITDA | -1.26 |
EV / EBIT | -1.21 |
EV / FCF | -5.43 |
Financial Position
The company has a current ratio of 0.29, with a Debt / Equity ratio of 0.96.
Current Ratio | 0.29 |
Quick Ratio | 0.21 |
Debt / Equity | 0.96 |
Total Debt / Capitalization | 48.93 |
Cash Flow / Debt | -0.99 |
Interest Coverage | -63.78 |
Financial Efficiency
Return on equity (ROE) is -4.79% and return on capital (ROIC) is -180.77%.
Return on Equity (ROE) | -4.79% |
Return on Assets (ROA) | -1.36% |
Return on Capital (ROIC) | -180.77% |
Revenue Per Employee | 189.76K |
Profits Per Employee | -1.64M |
Employee Count | 120 |
Asset Turnover | 0.16 |
Inventory Turnover | 2.78 |
Taxes
Income Tax | 10.00K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 20.32% in the last 52 weeks. The beta is 0.51, so Celularity 's price volatility has been higher than the market average.
Beta | 0.51 |
52-Week Price Change | 20.32% |
50-Day Moving Average | 2.4 |
200-Day Moving Average | 3.2 |
Relative Strength Index (RSI) | 45.76 |
Average Volume (20 Days) | 1.09M |
Income Statement
In the last 12 months, Celularity had revenue of $22.77M and earned -$196.29M in profits. Earnings per share was $-11.02.
Revenue | 22.77M |
Gross Profit | 6.75M |
Operating Income | -192.29M |
Net Income | -196.29M |
EBITDA | -183.95M |
EBIT | -192.29M |
Earnings Per Share (EPS) | -11.02 |
Balance Sheet
The company has $227.00K in cash and $65.42M in debt, giving a net cash position of -$65.19M.
Cash & Cash Equivalents | 227.00K |
Total Debt | 65.42M |
Net Cash | -65.19M |
Retained Earnings | -841.79M |
Total Assets | 128.84M |
Working Capital | -61.67M |
Cash Flow
In the last 12 months, operating cash flow was -$38.69M and capital expenditures -$4.05M, giving a free cash flow of -$42.73M.
Operating Cash Flow | -38.69M |
Capital Expenditures | -4.05M |
Free Cash Flow | -42.73M |
FCF Per Share | -2.4 |
Margins
Gross margin is 29.66%, with operating and profit margins of -844.44% and -862.04%.
Gross Margin | 29.66% |
Operating Margin | -844.44% |
Pretax Margin | -862% |
Profit Margin | -862.04% |
EBITDA Margin | -807.81% |
EBIT Margin | -844.44% |
FCF Margin | -187.66% |
Dividends & Yields
CELU does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -489.78% |
FCF Yield | -84.65% |
Analyst Forecast
Currently there are no analyst rating for CELU.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 29, 2024. It was a backward split with a ratio of 1:10.
Last Split Date | Feb 29, 2024 |
Split Type | backward |
Split Ratio | 1:10 |
Scores
Altman Z-Score | -10.85 |
Piotroski F-Score | 3 |